Efficacy and safety of anakinra (antagonist of the interleukin-1 receptor) in the treatment of periarticular inflammation in patients refractory to NSAID and / or steroids

Institut de Recerca HSCSP0 个研究点目标入组 20 人开始时间: 2014年4月25日最近更新: 2019年12月10日

适应症

试验速览

暂无简介。

•- Male and female patients over 18 years of age at the time of the screening visit.
•- Supraspinatus tendonitis, plantar fasciitis, trochanteric bursitis and / or lateral epicondylitis patients refractory to NSAIDs and / or corticosteroids, lack or loss of efficacy or contraindications.
•- Patients with a score on the VAS pain score greater than or equal to 6 cm
•- Patients able to understand the implications of the study and demonstrate it through voluntary signing of informed consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 20
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•- Pregnancy or breast-feeding
•- Participation in any clinical investigation within 3 months prior to drug administration.
•- Elective surgery patients during the trial.
•- History of drug or alcohol abuse during the 12 months prior to drug administration.

发起方

Institut de Recerca HSCSP